Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer
Breast Cancer - Metastasis
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
Metastatic breast cancer patients
Study Type
Study Phase
Phase 2
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Capecitabine and Mitomycin C
Type: Drug
Overall Status
This is an open-label, non-comparative efficacy and safety study of Capecitabine and Mitomycin C as first-line treatment in patients with previously untreated metastatic breast cancer.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Histologically/cytologically confirmed breast cancer

- Metastatic breast cancer, having at least one target lesion according to the RECIST criteria. Bone metastases, leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not acceptable as target lesions. Target lesions must be ≥ 10 mm longest diameter measured in one dimension using spiral CT, or ≥ 20 mm longest diameter measured in one dimension using conventional techniques. In addition to the definitions pertaining to the target lesion(s) from the RECIST criteria above, the target lesion(s) must not have been previously irradiated (newly arising lesions in previously irradiated areas are acceptable).

- Age > 18 years

- Signed informed consent obtained prior to initiation of any study-specific procedures or treatment

Exclusion Criteria:

- Prior cytotoxic chemotherapy or active/passive immunotherapy for metastatic breast disease

- Prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment

- Life expectancy < 3 months

- Not-ambulatory or with an ECOG performance status > 1

- Insufficient hematological, renal and hepatic functions:

- hemoglobin < 8.0 g/dL

- absolute neutrophils count (ANC) < 1.5 x 109/L

- platelet count < 100 x 109/L

- serum creatinine > 1.25 x N*

- total bilirubin > 2.0 x N*

- ASAT and/or ALAT > 2.5 x N* (in case of liver metastases > 5 x N*)

- alkaline phosphatase > 2.5 x N* (in case of liver metastases > 5 x N*, in case of bone metastases > 10 x N*) *N = upper limit of standard range

- Severe renal impairment [creatinine clearance < 30 mL/min (calculated according to cockcroft and Gault)]
Center of oncology
Split, Croatia
Status: Recruiting
Contact: Eduard Vrdoljak, MD PhD - 00385-21-556-129 -
Start Date
March 2006
Croatian Cooperative Group for Clinical Research in Oncology
Croatian Cooperative Group for Clinical Research in Oncology
Record processing date processed this data on July 28, 2015 page